Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
06:22pm, Tuesday, 09'th Jun 2026
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
01:16pm, Tuesday, 09'th Jun 2026
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
06:19pm, Friday, 05'th Jun 2026
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
04:15pm, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
12:50pm, Tuesday, 19'th May 2026
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
03:12am, Saturday, 16'th May 2026
Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:10pm, Wednesday, 13'th May 2026
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma to present at upcoming investor conferences
04:15pm, Thursday, 07'th May 2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
RPRX vs. AMGN: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 06'th May 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the be
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
11:41am, Wednesday, 06'th May 2026
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?
10:15am, Wednesday, 06'th May 2026
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
10:06am, Wednesday, 06'th May 2026
Royalty Pharma (RPRX) came out with quarterly earnings of $1.3 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.06 per share a year ago.
Royalty Pharma reports first quarter 2026 results
07:00am, Wednesday, 06'th May 2026
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected t
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Thursday, 30'th Apr 2026
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
